Catalent Expands Clinical Supply Capabilities
Catalent completes $4.6 million expansion at Singapore clinical supply facility and marks 20 years in the region.
Catalent Pharma Solutions announced on Feb. 28, 2018 the completion of a two-year, $4.6 million expansion at its Singapore clinical supply facility. The expansion added GMP space for secondary packaging, doubled ambient storage, and quadrupled cold storage capacity at the site. The site, which has almost tripled in size since opening in 1998, measures almost 20,000-sq. ft. and is described by the company as a key strategic hub in its Asia-Pacific network and global clinical supply business.
“We are particularly pleased to have completed the expansion in a year that marks the 20th anniversary of what was Catalent’s first facility in the Asia-Pacific region,” said Bernie Clark, VP Marketing, Catalent Clinical Supply Services in a company press release. “Supported by many long-serving employees, the Singapore site has undergone tremendous growth over the past two decades and now routinely distributes to 18 countries in the region.”
The company has facilities in the United States, United Kingdom, Germany, Japan, and China, and more than 50 audited depots.
Source: Catalent Pharma Solutions
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Market Demands and Emerging Technologies Shape Outsourcing Models
June 5th 2025Trends in certain forms of drug delivery, as well as the emergence of artificial intelligence, are playing roles in evolving the nature of partnerships, but there are new types of partnerships gaining steam as well.
